Immunohistochemical study of Ki-67 and DNA topoisomerase II in human endometrium

Modern Pathology

Volumn 10, Issue 4, 1997, Pages 289-294

  Ito, Kivoshi ^a   Sasano, Hironobu ^a   Yabuki, Noritaka ^a   Matsunaga, Gen ^a   Sato, Shinji ^a   Kikuchi, Akihiko ^b   Yajima, Akira ^a   Nagura, Hiroshi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MITSUBISHI KAGAKU INSTITUTE OF LIFE SCIENCES   (Japan)

Author keywords

carcinoma; endometrium; hyperplasia; immunohistochemistry; Ki 67; prolifera tion; topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); MONOCLONAL ANTIBODY KI 67; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; DNA TOPOISOMERASES, TYPE II; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PRECANCEROUS CONDITIONS;

EID: 0031011781     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sasano H, Watanabe K, Ito K, Sato S, Yajima A. New concepts in the diagnosis and prognosis of endometrial carcinoma. Pathol Annu 1994;2:231-49.
2. Sasano H. Emerging new technologies for evaluating endometrial hyperplasia and carcinoma. In: Weinstein RS, editor. Advances in pathology and laboratory medicine. Vol. 7. St. Louis: Mosby, 1994: 517-32.
3. Sasano H, Imatani A, Shizawa S, Suzuki S, Nagura H . Cell proliferation and apoptosis in normal and pathologic human adrenal. Mod Pathol 1995;8:11-7.
4. Baisch H, Gerdes J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet 1987;20:387-91.
5. Hall PA, Levinson DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of dysregulated expression in some neoplasms. J Pathol 1990;162:285-94.
6. Uemura T, Ohkura H, Adachi K, Miyake M, Nozaki N, Kikuchi A. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 1987;50:917-25.
7. Heck MM, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 1988;86:1086-90.
8. Hsiang YH, Wo HY, Liu LF. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988;48:3230-5.
9. Hwang JL, Shy SH, Chen AY, CC Juan, Whang PJ. Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. Cancer Res 1989;49:958-62.
10. Kaufmann SH, McLaughlin SJ, Kastan MB, Liu LF, Karp JE, Burke PJ. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 1991;51:3534-43.
11. Yabuki N, Sasano H, Kato K, Ohara S, Toyota T, Nagura H, et al. Immunohistochemical study of DNA topoisomerase in human gastric disorders. Am J Pathol 1996;149:997-1007.
12. Schneider E, Hsiang YH, Liu LF. DNA topoisomerases as anticancer drug targets. Adv Pharmacol 1990;21:149-83.
13. Nitiss JL, Liu YX, Harbury P, Jannatipour R, Wasserman R, Wang JC. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 1992; 52:4467-72.
14. Prosperi E, Sala E, Negri C, Oliani R, Supino R, Astraldi RG, et al. Topoisomerase II alpha and beta in human tumor cells grown in vitro and in vivo. Anticancer Res 1992;12:2093-9.
15. Sullivan DM, Glisson BS, Hodges PK, Smallvvood KS, Ross WE. Proliferation dependence of topoisomerase II-mediated drug action. Biochemistry 1986;25:2248-56.
16. Webb CD, Latham MD, Lock RB, Sullivan DM. Attenuated topoisomerase II content directly correlates with low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 1991;51:6543-9.
17. Silverberg SG. Hyperplasia and carcinoma of the endometrium. Semin Diagn Pathol 1988;5:135-53.
18. Sato S. Evaluation of the degree of biological behavior in endometrial hyperplasia and endometrial carcinoma: an investigation of proliferative activity, oncogene, and extracellular matrix. Acta Obstet Gynecol Jpn 1993;45:776-98.
19. Silverberg SG. The uterine corpus. In: Silverberg SG, editor. Principles and practice of surgical pathology. New York: Churchill-Livingstone, 1990:1729-71.
20. Ito K, Sasano H, Watanabe K, Ozawa N, Sato S, Yajima A. Immunohistochemical study of PCNA (proliferating cell nuclear antigen) in normal and abnormal endometrium. Int J Gynecol Cancer 1993;3:122-7.
21. Nielsen AL, Nyholm HCJ, Engel P. Expression of MIB-1 (paraffin Ki-67) and AgNOR morphology in endometrial adenocarcinomas of endometrioid type. Int J Gynecol Pathol 1994; 13:37-44.
22. Nielsen AL, Nyholm HCJ. Endometrial adenocarcinoma of endometrioid subtype with squamous differentiation: an immunohistochemical study of MIB-1 (Ki-67 paraffin), cathepsin D, and C-erb-B2 protein (p185). Int J Gynecol Pathol 1995;14:230-4.
23. Kuwashima Y, Uehara T, Kishi K, Shiromizu K, Matsuzawa M, Takayama S. Proliferative and apoptotic status in endometrial adenocarcinoma. Int J Gynecol Pathol 1995;14:45-9.
24. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73.
25. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989;28:8154-60.
26. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, et al Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991;51:6592-5.
27. Fogt F, Gibbons D, Hallgrimsson J, Holden J. Alder SL, O'Brien MJ. Comparison of topoisomerase II α and MIB1 expression in benign, dysplastic and malignant gastric mucosal biopsies [abstract]. Mod Pathol 1996;9:63A.
28. Heck M, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci U S A 1988;85:1086-90.
29. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992;52:1666-74.
30. Binaschi M, Capranico G, De IP, Mariani M, Supino R, Tinelli S, et al. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int J Cancer 1990;45:347-52.